Effects of dexamethasone on carnitine metabolism in liver and extrahepatic tissues.
The in vivo effects of dexamethasone administration on liver and extrahepatic tissue carnitine concentrations were assessed in 48-h-starved rats. In heart and kidney, but not in liver, dexamethasone significantly increased total carnitine concentration. Acute (2.5 h) treatment with 2-tetradecylglycidate (TDG), a specific inhibitor of carnitine palmitoyl transferase 1, not only increased total hepatic carnitine concentrations, but also permitted an effect of dexamethasone (a further increase in hepatic carnitine concentration). The results are discussed in terms of acute (substrate-mediated) and chronic (hormonal) control of carnitine turnover.
D000818:Animals; D002331:Carnitine / Q000378:metabolism*; D002334:Carnitine O-Palmitoyltransferase / Q000037:antagonists & inhibitors; D003907:Dexamethasone / Q000494:pharmacology*; D004852:Epoxy Compounds / Q000494:pharmacology; D005227:Fatty Acids / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D005508:Food Deprivation; D007668:Kidney / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism*; D051381:Rats
D004852:Epoxy Compounds; D005227:Fatty Acids; D003907:Dexamethasone; D002334:Carnitine O-Palmitoyltransferase; C021756:2-tetradecylglycidic acid; D002331:Carnitine